DuoNeb may be a sterile inhalation resolution containing a mixture of bronchodilator and ipratropium.bronchodilator and ipratropium square measure bronchodilators that relax muscles within the airways and increase air flow to the lungs.
DuoNeb is employed as Associate in Nursing indrawn medication to forestall spasm in folks with chronic impedingpulmonic sickness (COPD) World Health Organization also are exploitation different medicines to manage their condition.
DuoNeb might also be used for functions ex-directory during this medication guide.
Submit your review
Combivent, Combivent Respimat, DuoNeb
Get emergency medical help if you have any of these signs of an allergic reaction to DuoNeb: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Stop using DuoNeb and call your doctor at once if you have a serious side effect such as:
wheezing, choking, or other breathing problems (especially after starting a new canister of this medicine);
chest pain, pounding heartbeats or fluttering in your chest;
dangerously high blood pressure (severe headache, anxiety, uneven heartbeats);
swelling of your ankles or feet;
eye pain, or seeing halos around lights;
painful or difficult urination; or
low potassium (confusion, extreme thirst, increased urination, leg discomfort, muscle weakness or limp feeling).
Other common DuoNeb side effects may include:
mild headache; or
cold symptoms such as stuffy nose, sneezing, cough, or sore throat.
The recommended dose of Ipratropium Bromide and Albuterol Sulfate Inhalation Solution is one 3 mL vial administered 4 times per day via nebulization with up to 2 additional 3 mL doses allowed per day, if needed. Safety and efficacy of additional doses or increased frequency of administration of Ipratropium Bromide and Albuterol Sulfate Inhalation Solution beyond these guidelines has not been studied and the safety and efficacy of extra doses of albuterol sulfate or ipratropium bromide in addition to the recommended doses of Ipratropium Bromide and Albuterol Sulfate Inhalation Solution have not been studied. The use of Ipratropium Bromide and Albuterol Sulfate Inhalation Solution can be continued as medically indicated to control recurring bouts of bronchospasm. If a previously effective regimen fails to provide the usual relief, medical advice should be sought immediately, as this is often a sign of worsening COPD, which would require reassessment of therapy. A Pari-LC-Plus™ nebulizer (with face mask or mouthpiece) connected to a PRONEB™ compressor was used to deliver Ipratropium Bromide and Albuterol Sulfate Inhalation Solution to each patient in one U.S. clinical study. The safety and efficacy of Ipratropium Bromide and Albuterol Sulfate Inhalation Solution delivered by other nebulizers and compressors have not been established. Ipratropium Bromide and Albuterol Sulfate Inhalation Solution should be administered via jet nebulizer connected to an air compressor with an adequate air flow, equipped with a mouthpiece or suitable face mask.